Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study

Antonio Rodriguez-Poncelas¹,², Josep Garre-Olmo², Josep Franch-Nadal³,⁴, Javier Diez-Espino⁵, Xavier Mundet-Tuduri⁴,⁶, Joan Barrot-De la Puente⁷, Gabriel Coll-de Tuero¹,²* and RedGDPS Study Group

Abstract

Background: The objective of this study was to determine the prevalence of chronic kidney disease (CKD) and the different stages of CKD in patients with type 2 diabetes mellitus (DM2) treated in primary care consults in Spain.

Methods: A national cross-sectional study was performed in primary care consults. The following data were collected: demographic and anthropometric information; list of present cardiovascular risk factors (CVRF); previous macrovascular and microvascular disease history; physical examination and analytical data from the previous 12 months, including the urine albumin-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) to evaluate renal function.

Results: With regard to the patients, 27.9% presented some degree of CKD as follows: 3.5% with stage 1; 6.4% with stage 2; 16.8% with stage 3 (11.6% with stage 3A and 5.2% with stage 3B); and 1.2% with stages 4 and 5. The prevalence of patients with UACR ≥ 30 mg/g was 15.4% (13% microalbuminuria and 2.4% macroalbuminuria). Renal impairment (RI) was found in 206 patients (18%) of whom 133 patients (64.6%) was stage 3A, 60 patients (29.1%) was stage 3B and 13 patients (6.3%) stages 4 and 5. Among patients with RI, 143 patients (69.4%) had normoalbuminuria.

The following variables were significantly associated with CKD: age; sex (women); systolic arterial blood pressure (SABP) ≥ 150 mmHg; and a previous history of cardiovascular disease.

Conclusions: The results showed that the prevalence for any type of CKD was 27.9%. A systematic determination of UACR and eGFR may contribute to an early diagnosis, thus allowing intervention during the initial stages of the disease when treatment is more efficient.

Keywords: Cross-sectional study, Chronic kidney disease, Renal impairment, Albuminuria, Type 2 diabetes mellitus
and stratification of CKD in the Kidney Disease Outcomes Quality Initiative (KDOQI) [10] define the following as diagnostic criteria for CKD: a eGFR value below 60 ml/min/1.73 m² in a time period equal or superior to three months or the presence of renal lesion with or without reduced GFR in a time period equal or superior to three months. The concept of renal lesion is defined as the presence of structural or functional alterations of the kidney detected directly by histological alteration in the renal biopsy or indirectly by an UAE increase, alterations in the urine sediment, or differences identified with imaging techniques. The combination of these clinical criteria is the basis for the classification of CKD in five stages.

The objective of this study was to establish the prevalence of CKD and the different stages of CKD in patients with DM2 treated in primary care consults in Spain.

**Methods**

**Study design and population**

This study was a national cross-sectional study performed in primary care consults. Estimating a higher prevalence of chronic kidney disease in women than in men, and higher in those over 64 years, there was a proportional stratified sampling. A sample size of 1153 patients was calculated assuming a 0.05 alpha error and 2.5% precision for an estimated prevalence of 25%. Foreseeing a 20% loss due to erroneous or incomplete data, the size of the sample was increased to 1383 patients. During the recruitment, 1279 patients were included in the study, but 134 (10.4%) patients were discarded because of incomplete or erroneous data. To rule out a bias attributable to patients discarded we compared each other groups, of all variables compared did not show differences. The total number of valid patients for the final analysis was 1145. The patients included both genders and were over 40 years old. Moreover, the patients were diagnosed with DM2, and they had all of the variables necessary for the study included in their clinical history. Each researcher included 15 patients who met the inclusion criteria, a maximum of 3 patients per day. The patients were selected by convenience sample of the first 3 DM2 patients each day who came to the consult for any reason and met the inclusion criteria until complete the number of participants per researcher.

The information for each participant was collected in the period from February to July 2011. The Ethical and Clinical Investigation Committee of the Institut d’Assistència Sanitària (IAS) in Salt, Girona, Spain approved the study. To obtain the necessary data for this study from the clinical history of patients, all participants provided written informed consent.

**Variables and procedure**

The following variables were collected during the visit: age, gender, ethnicity, weight, height, body mass index (BMI) was calculated as weight in kilograms divided in meters squared; obesity was defined as BMI ≥ 30 kg/m², abdominal waist circumference, CVRF. Cardiovascular diseases (CVD) was collected through the medical record as a history of Stroke (ischaemic cerebrovascular disease) included only symptomatic brain infarction, and did not include silent brain infarction, transient ischaemic attack or brain haemorrhage. CHD included a previous history of myocardial infarction, angina pectoris, the presence of coronary interventions or the presence of ECG abnormalities suggestive of CHD. PAD was diagnosed by an ankle-brachial pressure index of < 0.9 and/or two absent foot pulses. Diabetes mellitus was defined as fasting glucose ≥ 126 mg/dL or non-fasting glucose ≥ 200 mg/dL or use of glucose-lowering drugs. Hypertension was defined as SBP of 140 mmHg or greater, DBP of 90 mmHg or greater, or use of antihypertensive medications irrespective of BP. Hyperlipidemia was defined as total cholesterol ≥ 250 mg/dL, LDL cholesterol > 155 mg/dL, HDL cholesterol < 40 mg/dL in men and < 48 mg/dL in women, triglycerides > 150 mg/dL or pharmacologic lipid lowering treatment. Cigarette smoking was defined as never/past/current.

The following clinical and analytical measurements were collected: DM2 duration, arterial pressure (average of the last three determinations), drugs taken by the patient at the time the data were collected (antidiabetic, antihypertensives, hypolipemiant, antiplatelet, and anticoagulants). Basal glycaemia, glycosylated haemoglobin (HbA1c), plasmatic haemoglobin, total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, triglycerides, serum creatinine after overnight fasting for at least 12 hr, and the urine albumin-creatinine ratio (UACR) in a urine sample collected in the first morning urine specimen, using the most recent value of the last 12 months. The analysis determination was not performed by a single laboratory.

In this study, the presence of CKD was based on KDOQI [10] criteria as follows: patients with GFR < 60 ml/min/1.73 m² or the presence of renal damage if UACR values were elevated (UACR ≥ 30 mg/g). Considering that all of the values for serum creatinine were measured using the modified kinetic method of Jaffe, the MRDR-IDMS (Modification of Diet in Renal Disease study- isotope dilution mass spectrometry) equation [11] was used to calculate the GFR. Albuminuria was defined as a UACR of 30 mg/g or more. Microalbuminuria was defined as a UACR ranging from 30 to 299 mg/g, and macroalbuminuria was defined as a UACR of 300 mg/g or more. CKD was defined as the presence of albuminuria or eGFR < 60 mL/min/1.73 m². Stages of CKD were defined as follows: stage 1 (eGFR ≥ 90 mL/min/1.73 m² and UACR ≥30 mg/g); stage 2 (eGFR 60–89 mL/min/1.73 m² and UACR ≥30 mg/g); stage 3 (eGFR 30–59 mL/min/1.73 m²
regardless of UACR); stage 4 (eGFR 15–29 mL/min/1.73 m² regardless of UACR); and stage 5 (eGFR <15 mL/min/1.73 m² regardless of UACR). Two of three determinations of eGFR or/and UACR, in a period of three or more months, should be presented normal or altered values. The cases that did not fulfil this requisite were excluded from the final analysis of the study. The same requirement of two or more measurement in three months was applied to a classification of presence CKD or absence CKD ("no CKD").

Statistical analysis
Measurements of central tendency and dispersion were used to perform a descriptive analysis of the quantitative variables studied. Absolute and relative frequencies were used for qualitative variables. The global CKD prevalence was calculated, and the CKD prevalence of each stage was also calculated. Age group and sex stratified the results. Bivariate analysis of contrasting hypotheses was used to establish the presence of statistically significant differences in the clinical characteristics of the patients depending on the presence or absence of CKD and its stage. Proportion comparison was performed by means of a Chi-squared test with Yates correction when it was considered necessary. The means of the clinical and analytical variables were compared with the ANOVA test and the medians were compared with the the Kruskal-Wallis test depending on the distribution of the data. The normal distribution of continuous variables was contrasted with the Shapiro-Wilk test. The Bonferroni correction was used for multiple testing. The association degree between the demographic and clinical characteristics of the patients and the presence or absence of CKD was established with a binomial logistic regression. The results were expressed as absolute numbers, percentages, medians, standard deviations, odd ratios, and CI of 95%. Statistical significance was set at 0.05 when contrasting hypotheses. Data

Table 1 Clinical and metabolic characteristics of participants

|                      | Total   | Men       | Women     | P      |
|----------------------|---------|-----------|-----------|--------|
|                      | N (%)   | 1,145     | 689 (60.2%) | 456 (39.8%) |        |
| Age (years)          | 66.8 ± 11.3 | 66.3 ± 11.4 | 67.4 ± 10.9 | 0.089  |
| Duration diabetes (years) | 9.1 ± 6.7 | 8.8 ± 6.5 | 9.4 ± 6.9 | 0.250  |
| BMI (kg/m²)          | 30.3 ± 5.2 | 29.6 ± 4.5 | 31.1 ± 6.0 | 0.001  |
| Obesity, n(%)        | 533 (46.5) | 297 (43.1) | 236 (51.8) | 0.004  |
| Abdominal waist circumference (cm) | 100.0 ± 17.1 | 103.5 ± 12.1 | 100.2 ± 13.6 | 0.001  |
| Smoking (n%)         |         |           |           |        |
| Yes                  | 158 (13.8) | 123 (17.9) | 35 (7.7) | 0.001  |
| Ex-smoker            | 345 (30.1) | 312 (45.2) | 33 (7.2) |        |
| Never                | 642 (56.1) | 254 (36.9) | 388 (85.1) |        |
| HbA1c (%)            | 7.3 ± 1.3 | 7.2 ± 1.2 | 7.3 ± 1.3 | 0.089  |
| Hypertension (n%)    | 860 (75.1) | 514 (74.6) | 346 (75.9) | 0.625  |
| Systolic Blood Pressure (mmHg) | 134.5 ± 13.2 | 134.3 ± 12.6 | 134.8 ± 14.0 | 0.984  |
| Diastolic Blood Pressure (mmHg) | 77.0 ± 9.1 | 77.1 ± 8.9 | 76.8 ± 9.3 | 0.477  |
| Total cholesterol (mmol/L) | 4.70 ± 0.93 | 4.63 ± 0.99 | 4.89 ± 0.90 | 0.001  |
| LDL cholesterol (mg/dl) | 2.79 ± 0.83 | 2.74 ± 0.86 | 2.84 ± 0.78 | 0.021  |
| non-HDL cholesterol (mg/dl) | 3.49 ± 0.91 | 3.46 ± 0.96 | 3.35 ± 0.90 | 0.086  |
| HDL cholesterol (mg/dl) | 1.29 ± 0.35 | 1.17 ± 0.31 | 1.33 ± 0.37 | 0.001  |
| Triglycerides (mg/dl) | 1.69 ± 0.96 | 1.70 ± 1.04 | 1.68 ± 0.87 | 0.450  |
| Plasmatic creatinine (mg/dl) | 0.93 ± 0.3 | 1.01 ± 0.3 | 0.8 ± 0.2 | 0.001  |
| eGFR ml/min/1.73 m² | 79.9 ± 23.5 | 80.4 ± 22.4 | 78.6 ± 23.6 | 0.142  |
| Albumin/creatinine ratio (mg/g) | 39.2 ± 144.3 | 46.3 ± 160.5 | 28.4 ± 92.4 | 0.979  |
| Coronary heart disease (n%) | 177 (15.4) | 137 (19.9) | 34 (7.5) | 0.001  |
| Heart failure (n%)   | 91 (7.9) | 49 (7.1) | 42 (9.2) | 0.199  |
| Peripheral vascular disease (n%) | 98 (8.5) | 85 (12.3) | 13 (2.9) | 0.001  |
| Stroke (n%)          | 79 (6.9) | 57 (8.3) | 22 (4.8) | 0.024  |

BMI = Body Mass Index. HbA1c = glycosilated hemoglobin. eGFR = estimated glomerular filtration rate. LDL cholesterol = Low Density Lipoprotein cholesterol. HDL cholesterol = High Density Lipoprotein cholesterol.
Analysis and processing were performed using the SPSS 14.0 statistical program for Windows.

**Results**

Table 1 shows the clinical and demographic characteristics of the 1145 participants. When comparing men and women, no significant differences were detected with age, HbA1c levels, and arterial pressure. Men presented higher values for creatinine, because men have more muscle mass than women, and smoking than women. Total cholesterol levels and HDL cholesterol were higher in women than in men. The prevalence of coronary disease, ictus, and peripheral vascular disease was higher in men than in women.

Table 2 shows the prevalence of the different types of kidney disease. Prevalence of CKD in patients was 27.9% (CI 95% = 25.2 - 30.5), and the CKD prevalence was classified into the following stages: 3.5% with stage 1 (CI 95% = 2.3 - 4.6); 6.4% with stage 2 (CI 95% = 4.9 - 7.8); 16.8% with stage 3 (CI 95% = 14.6 - 19.0), including 11.6% with stage 3A (CI 95% = 9.7 - 13.5) and 5.2% with stage 3B (CI 95% = 3.9 - 6.5); and 1.2% with stages 4 and 5 (CI 95% = 0.4 - 1.7). Due to their low prevalence, stages 4 and 5 were analysed together. Prevalence for UACR ≥ 30 mg/g was 15.4% (CI 95% = 13.2 - 17.5), microalbuminuria 13% (CI 95% = 11.1 - 17.5), and macroalbuminuria 2.4% (CI 95% = 1.4 - 3.2). Renal impairment (RI) (eGFR <60) was found in 206 patients (18%) of whom 133 patients (64.6%) was stage 3A, 60 patients (29.1%) was stage 3B and 13 patients (6.3%) stages 4 and 5. Among patients with RI, 143 patients (69.4%) had normoalbuminuria.

The comparison of diabetic patients with CKD vs diabetic patients with no CKD showed no significant difference in their sex, BMI, weight, systolic arterial blood pressure (SABP), diastolic arterial blood pressure (DABP), tobacco use, or lipid profile values. No significant differences between the groups were found when comparing DM2 duration or glycaemia levels. However, diabetic patients with CKD had higher HbA1c values than diabetic patients without CKD. Diabetic patients with CKD had elevated creatinine values. Creatinine values, in CKD patients, increased as the disease progressed. Age was significantly correlated with CKD with increasing percentages of elderly patients in the most advanced stages. Patients diagnosed with arterial hypertension had a higher CKD prevalence (Table 3).

The multivariate analysis by binomial logistic regression demonstrated that CKD was significantly associated with age. Older age was associated with higher CKD prevalence among women if SABP ≥ 150 mm Hg. Even at SABP ≥ 140 mm Hg, an increased CKD prevalence was observed. A previous clinical history of ischemic cardiac disease, cardiac insufficiency, or peripheral vascular disease was significantly associated with increased CKD prevalence (Table 4).

**Discussion**

To the best of our knowledge, this study was the first epidemiological investigation on CKD prevalence using the KDOQI criteria on Spanish patients attending primary care consults. Different studies have been performed in Spain on IR prevalence in DM2 patients [12-15]. The study by Lou Arnal et al. [16] has been the only report published on CKD prevalence in DM2 patients in primary care consults, and their study was performed with only one UACR measurement in Alcañiz, Teruel, Spain. The results of the PERCEDIME2 study showed an elevated CKD prevalence in DM2 patients in primary care consults in Spain. DM2 patients with CKD, 18% had a eGFR

**Table 2 Prevalence of different types of chronic kidney disease in Spain**

| eGFR (mL/min per 1.73 m²) | Normoalbuminuria | Microalbuminuria | Macroalbuminuria |
|---------------------------|-------------------|------------------|------------------|
| ≥ 90 (Stage 1)            | 298 (26%)         | 36 (3.14%)       | 4 (0.35%)        |
| 60-89.9 (Stage 2)         | 528 (46.1%)       | 68 (6%)          | 5 (0.45%)        |
| 45-59.9 (Stage 3A)        | 99 (8.65%)        | 26 (2.3%)        | 8 (0.7%)         |
| 30-44.9 (Stage 3B)        | 40 (3.5%)         | 15 (1.3%)        | 5 (0.45%)        |
| < 30 (Stages 4–5)         | 4 (0.35%)         | 4 (0.35%)        | 5 (0.45%)        |
| UACR ≥ 30 mg/g            | Normoalbuminuria | Microalbuminuria | Macroalbuminuria |
| N (%)                     | 969 (84.6%)       | 149 (13.0%)      | 27 (2.4%)        |
| eGFR ≥ 60                 | 939 (82%)         |                  |                  |
| eGFR < 60                 | 206 (18%)         |                  |                  |
| Any type of CKD           | 319 (27.9%)       |                  |                  |

eGFR = estimated glomerular filtration rate. ACR = albumin-creatinine ratio. CKD = Chronic Kidney Disease.
In patients with a eGFR > 60 ml/min/1.73 m², 9.9% presented albuminuria. In the study by Lou Arnal et al. [16], 34.5% of DM2 patients presented some stage of CKD, 16.1% of DM2 patients had albuminuria (14.3% microalbuminuria and 1.8% macroalbuminuria), and 9.4% of the patients with eGFR ≥ 60 ml/min/1.73 m² had albuminuria. Vinagre et al. [17] found a prevalence of 20% for RI and 16.7% for albuminuria. In another study in Spain [8] the prevalence of different types of renal disease in DM2 was: 34.1% for any type of CKD, 22.9% RI and 19.5% for albuminuria. In a study performed in primary care centres in the Netherlands, van der Meer et al. [18] observed that 27.6% of DM2 patients had CKD and that 13.6% of these DM2 patients had albuminuria. Another study in the United Kingdom [19] showed that 31% of diabetic patients had a GFR < 60 ml/min/1.73 m² and 37% of these patients had albuminuria. Pugliese et al. [20] found that the prevalence of RI was 18.7% and CKD 37.5% with the MDRD Study equation. Penno et al. [21] observed that in patients with renal impairment, as identified by an estimated glomerular filtration rate (eGFR) less than 60 ml/min per 1.73 m², 56.6% were normoalbuminuric, 30.8% were microalbuminuric, and 12.6% were macroalbuminuric. In the United States Plantinga et al. [22] showed that 32.9% of U.S population had CKD and that 19.4% of these patients had albuminuria. In a study performed in Australia, Thomas et al. [23] observed that 23.1% of DM2 patients had a GFR < 60 ml/min/1.73 m² and that 34.6% of these patients had albuminuria (27.3% microalbuminuria and 7.3% macroalbuminuria). In a Japanese study, Ohta et al. [24] found that 46% of DM2 patients had CKD and that 36.1% of DM2 patients had albuminuria, and this group reported that 25.2% of these patients had a GFR below 60 ml/min/1.73 m². A study performed in Thailand [25] reported that DM2 patients in primary care consulted had an albuminuria prevalence of 37.2% (26% microalbuminuria and 11.2% macroalbuminuria). In a study performed in Shanghai, Jia et al. [26] reported that 29.6% of DM2 patients had CKD and that 26.2% of these patients

| Table 3 Clinical characteristics of diabetic patients with any degree of CKD compared with diabetics with no CKD |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| N = 1145 (%) | 826 (72.1) | 40 (3.5) | 73 (6.4) | 133 (11.6) | 60 (5.2) | 13 (1.2) |
| Age (years) | 64.9 ± 10.8 | 62.8 ± 10.7 | 67.6 ± 11.1 | 74.4 ± 8.6 | 75.2 ± 10.0 | 73.6 ± 10.6 | 0.001 |
| Gender (Men) | 511 (61.9) | 25 (62.5) | 47 (64.4) | 63 (47.4) | 36 (60.0) | 7 (53.8) | 0.053 |
| BMI (kg/m²) | 30.1 ± 5.2 | 30.4 ± 4.4 | 30.4 ± 5.3 | 30.7 ± 5.1 | 30.9 ± 6.0 | 30.1 ± 5.1 | 0.985 |
| Abdominal waist circumference (cm) | 99.8 ± 16.5 | 101.7 ± 11.7 | 99.4 ± 19.3 | 99.8 ± 19.8 | 100.4 ± 19.1 | 105.5 ± 14.1 | 0.950 |
| Smoking (n%) | Yes | 118 (14.3) | 12 (30.0) | 13 (17.8) | 8 (6.0) | 5 (8.3) | 2 (15.4) | 0.025 |
| | Ex-smoker | 239 (28.9) | 11 (27.5) | 22 (30.1) | 50 (37.6) | 19 (31.7) | 4 (30.8) |
| | Never | 469 (56.8) | 17 (42.5) | 38 (52.1) | 75 (56.4) | 36 (60.0) | 7 (53.8) |
| HbA1c (%) | 7.2 ± 1.2 | 7.8 ± 1.6 | 7.7 ± 1.3 | 7.1 ± 1.2 | 7.0 ± 1.0 | 7.9 ± 1.9 | 0.001 |
| Duration of DM (years) | 8.5 ± 6.5 | 9.5 ± 6.6 | 9.7 ± 7.4 | 11.1 ± 8.5 | 11.0 ± 6.9 | 11.7 ± 8.7 | 0.986 |
| Glycaemia (mmol/L) | 8.05 ± 3.20 | 8.8± 3.23 | 9.00± 2.79 | 7.90± 2.63 | 7.48± 2.98 | 7.88± 3.40 | 0.002 |
| Hypertension (n%) | 578 (70.0) | 32 (80.0) | 60 (82.2) | 121 (91.0) | 56 (93.3) | 13 (100) | 0.001 |
| Systolic Blood Pressure (mmHg) | 134.0 ± 12.5 | 136.9 ± 15.9 | 136.6 ± 15.1 | 135.9 ± 14.2 | 134.2 ± 14.1 | 134.5 ± 16.9 | 0.610 |
| Diastolic Blood Pressure (mmHg) | 77.8 ± 8.7 | 79.3 ± 9.9 | 76.3 ± 9.6 | 74.2 ± 10.0 | 72.8 ± 8.8 | 71.7 ± 6.6 | 0.003 |
| Dyslipidaemia (n%) | 555 (67.2) | 27 (67.5) | 52 (71.2) | 97 (72.9) | 37 (61.7) | 8 (61.5) | 0.638 |
| Total cholesterol (mmol/L) | 4.75 ± 0.95 | 4.94 ± 1.12 | 4.78 ± 0.99 | 4.59 ± 0.89 | 4.65 ± 1.11 | 4.30 ± 0.91 | 0.113 |
| LDL cholesterol (mmol/L) | 2.81 ± 0.81 | 2.95 ± 1.00 | 2.76 ± 0.79 | 2.67 ± 0.85 | 2.64 ± 0.94 | 2.21 ± 0.56 | 0.082 |
| non-HDL cholesterol (mmol/L) | 3.50 ± 0.91 | 3.75 ± 1.07 | 3.60 ± 1.01 | 3.31 ± 0.91 | 3.45 ± 1.08 | 3.22 ± 0.94 | 0.064 |
| HDL cholesterol (mmol/L) | 1.24 ± 0.33 | 1.19 ± 0.33 | 1.18 ± 0.26 | 1.28 ± 0.43 | 1.17 ± 0.34 | 1.07 ± 0.25 | 0.244 |
| Triglycerides (mmol/L) | 1.63 ± 0.94 | 1.88 ± 0.94 | 1.89 ± 1.21 | 1.76 ± 1.03 | 1.90 ± 0.96 | 2.17 ± 1.07 | 0.477 |
| Plasmatic creatinine (mg/dl) | 0.8 ± 0.1 | 0.6 ± 0.1 | 0.9 ± 0.1 | 1.1 ± 0.1 | 1.5 ± 0.2 | 2.3 ± 0.5 | 0.001 |

CKD (1, 2, 3A, 3B, 4–5) different stages of CKD

P (Kruskall-Wallis test, Chi-squared test).

eGFR = estimated glomerular filtration rate. ACR = albumin-creatinine ratio. CKD = Chronic Kidney Disease. BMI = Body Mass Index. HbA1c = glycosilated hemoglobin. eGFR = estimated glomerular filtration rate. LDL cholesterol = Low Density Lipoprotein cholesterol. HDL cholesterol = High Density Lipoprotein cholesterol.
had albuminuria (22.8% microalbuminuria and 3.4% macroalbuminuria). Different prevalence of renal impairment and albuminuria among studies may due to the different methodology applied. Our study required that two of three determinations of eGFR or UACR values in two of three determinations in a period of three or more months. If these requirements were not met, new eGFR and UACR determinations were required. The patients that did not fulfil this requisite were excluded from the final analysis.

Early detection of CKD has important clinical implications. It is well known that a diminished eGFR is associated with increased global mortality and cardiovascular episodes [2,27-29]. Different epidemiological studies have demonstrated that increased UAE is an important risk factor for CKD in DM2 patients. A meta-analysis of these studies [30] has shown that increased UAE doubles the cardiovascular morbidity and mortality risk. Moreover, UAE values in the high range of normality even predict cardiovascular and renal complications [1,31]. Patients with DM2 and CKD have an elevated risk of cardiovascular and renal complications, thus requiring improved intervention and control [32,33]. Albuminuria and mortality association is linear in a logarithmic scale, and this risk doubles in patients with microalbuminuria with UACR levels within the optimal range independent of the eGFR and presence of other classic CVRF [5]. In the HUNT II study [34], the presence of albuminuria and reduced eGFR was associated with an increased risk of cardiovascular mortality. Astor et al. [35] reported that reduced eGFR and increased UAE independently increases the mortality risk for patients with CVRF, and the simultaneous occurrence of reduced eGFR and increased UAE was associated with an even higher risk. Our study found a high prevalence of PVD, different studies have shown a high prevalent PAD associated with microalbuminuria alone, reduced eGFR alone, and both reduced eGFR and microalbuminuria compared to those without microalbuminuria or reduced eGFR [36,37]. The higher prevalence in men may be related to the higher percentage of male smokers.

The present study had weaknesses and strengths. Although all autonomous communities were represented and efforts were made to ensure a representative distribution of the Spanish territory, this study was not a population-based study. The investigators were not randomly selected because only those willing to participate were involved in the study. The majority of these investigators were part of the RedGDPS (Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud, Network for the Study of Diabetes in Primary Health Care). Thus, it was impossible to dismiss investigator-related bias and which patients were included. Another source of bias can come from the frequency of visits by the patients. However, the fact that the results of the present study were similar to other studies indicates that these biases had little influence on the final data. Importantly, all patients included in this study had to present normal or altered eGFR and UACR values in two of three determinations in a period of three or more months. If these requirements were not met, new eGFR and UACR determinations were required. The patients that did not fulfil this requisite were excluded from the final analysis.

**Conclusion**

In conclusion, this study demonstrated that the prevalence of CKD in a sample of 1145 DM2 patients in primary care consults was 27.9%. A systematic determination of GFR and UACR would contribute to an earlier diagnosis, thus allowing intervention in early stages of the disease in which treatment is more efficacious.

**Abbreviations**

UACR: Urine albumin-creatinine ratio; CKD: Chronic kidney disease; CVRF: Cardiovascular risk factor; DM2: Type 2 diabetes mellitus; eGFR: Estimated glomerular filtration rate; MDRD: Modification of diet in renal disease; ESRD: End-stage renal disease; UAE: Urinary albumin excretion.

**Appendix I**

**Study investigators**

Alumn Bou A, Anguillo Martinez E, Arnatz Amoyo J, Artola Menendez S, Avila Lachica L, Barquilla Garcia A, Barroq de la Puente J, Barutell Rubio I, Belinchon Sanchez M, Benito Badorey B, Bobe Molina I, Bosch Costabella R, Bull Cosiales P, Carrarnana Barrera F, Carrillo Fernandez L, Canion Valero L, Casaseca Garcia P, Colt Lorendana C, Comas Samper J, Cuevas Lopez J, De la Sen C, Diez Espino J, Dominguez Coello S, Dominguez Navarro D, Egocheaga Cabello I, Ferrer Menduria X, Franch Nadel J, Garcia Aparicio JM, Garcia Gallego F, Garcia Soidan FJ, Garrido Redondo N, Gomez Garcia C, Gomez Gonzalez L, Gonzalez Pastor C, Granero Fernandez E, Grau Bartomeu

| Table 4 Factors associated with CKD in patients with type 2 diabetes |
|------------------|------------------|------------------|
| **OR (95% CI)**  | **OR (95% CI)**  | **OR (95% CI)**  |
| Age (years)      |                  |                  |
| < 50             | 1                |                  |
| 50-59            | 2.02 (0.93-4.41) |                  |
| 60-69            | 1.75 (0.82-3.76) |                  |
| 70-79            | 3.24 (1.53-6.86) |                  |
| >80              | 7.84 (3.50-17.54)|                  |
| Gender           |                  |                  |
| Men              | 1                |                  |
| Women            | 1.36 (1.01-1.84) |                  |
| Systolic Blood Pressure (mmHg) |          |                  |
| < 130            | 1                |                  |
| 130-139          | 0.85 (0.60-1.22) |                  |
| 140-149          | 1.01 (0.67-1.51) |                  |
| ≥150             | 1.61 (1.03-2.53) |                  |
| Duration of DM 2 (years) |          |                  |
|                  | 1.02 (1.01-1.04) |                  |
| Coronary heart disease | 1.54 (1.04-2.28) |                  |
| Heart failure    | 2.69 (1.64-4.40) |                  |
| Peripheral vascular disease | 2.71 (1.69-4.35) |                  |

(CKD compared with “no CKD”).

CKD = Chronic Kidney Disease. OR = Odds Ratio. CI = Confident Interval.
Lilly not involved in the study design of analysis of results. and Lilly (USA) for funding the project. Laboratories Boehringer Ingel and We thank RedGDPS for the support, all the researches who participated in the

Acknowledgements

analysed and interpreted the data. All authors contributed to the drafting of the article and gave final approval of the version to be published.

Competing interest

The authors declare that there is no duality of interest associated with this manuscript.

Authors’ contributions

ARP, JD E and JGO contributed to the conception and design, ARP and JGO contributed to the drafting of the manuscript.

References

1. Levey AS, Atkins R, Corej J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int 2007; 72:287–295.

2. Sarnak MJ, Levey AS, Schoeller DC, Corej J, Culliton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney disease in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003, 108:2154–2169.

3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:2386–2397.

4. Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85–97.

5. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073–2081.

6. Collins AJ, Foley RN, Hozo SP, Huang Y, Li Y, Liu W, et al: Prevalence and risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation. J Am Soc Nephrol 2010, 21:802–809.

7. Plantinga LC, Cresco DW, Corej J, Miller ER, Saran R, Yee J, et al: Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010, 5:675–682.

8. Thomas MC, Weeke AI, Broadway JG, Cooper ME, Mathew TH: The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust 2006, 185:10–14.

9. Kramer CK, Leitão CB, Pinto LC, Silveira SP, Gross JL, Canani LH: Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and nonalbuminuria. Diabetes Care 2007, 30:1998–2000.

10. National kidney foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39: Suppl 1:S1–S266.

11. Levey AS, Corej J, Greener T, Stevens LA, Zhang YL, Hendriksen S, et al: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247–254.

12. Marín R, Coca A, Tranche S, Rodríguez Mañas L, Abellán J, Moyà A: Prevalence of renal involvement in a population of type II diabetics followed up in primary care. Nefrologia 2002, 22:152–161.

13. Tranche Iparaguaiere S, Risco García A, Marín Irarrazábal R, Díaz González G, García Fernández A: Prevalence of “hidden” renal failure in the population suffering from type-2 diabetes. Aten Primaria 2005, 35:359–364.

14. Rodríguez-Poncelas A, Quezada Sabate M, Coll-de-Tuero G, Mata-Cases M, Rodriguez-Poncelas A, Ruiz Tamayo I, Sagreras Gonzalez FJ, Sanz Rebollo G, Sedano Garcia JI, Sierra Laguarta M, Serrano Martin R, Socías Buades I, Torres Balles A, Trends Rodriguez M, Ulbarri del Portillo I, Vazquez de Prada I, Vergara Fernandez I, Villaro Gaboros M.
28. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol* 2004, 15:1307–1315.

29. Nag S, Bilous R, Kelly W, Jones S, Roper N, Connolly V: All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the south tees diabetes mortality study. *Diabet Med* 2007, 24:10–17.

30. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. *Arch Intern Med* 1997, 157:1413–1418.

31. Rachmani R, Levi Z, Lidar M, Slavachevski I, Half-Onn E, Ravid M: Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. *Diabetes Res Clin Pract* 2000, 49:187–194.

32. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001, 286:421–426.

33. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008, 358:580–591.

34. Hallan S, Astor BC, Romundstad S, Aasarød K, Kvenild K, Coresh J: Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. *Arch Intern Med* 2007, 167:2490–2496.

35. Astor BC, Hallan S, Miller ER, Yeung E, Coresh J: Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. *Am J Epidemiol* 2008, 167:1226–1234.

36. O'Hare AM, Glidden DV, Fox CS, Hsu CY: High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the national health and nutrition examination survey 1999–2000. *Circulation* 2004, 109:320–323.

37. Baber U, Mann D, Shimbo D, Woodward M, Olin JW, Muntner P: Combined role of reduced estimated glomerular filtration rate and microalbuminuria on the prevalence of peripheral arterial disease. *Am J Cardiol* 2009, 104:1446–1451.

doi:10.1186/1471-2369-14-46

Cite this article as: Rodriguez-Poncelas et al.: Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. *BMC Nephrology* 2013 14:46.